Clinical Trial Update: Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

This document reports the results update of a Phase 2 trial comparing paclitaxel with or without cixutumumab as second-line therapy for metastatic esophageal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2015-06-03